JP2024517671A - ヘテロ二量体抗体およびその抗原結合断片 - Google Patents

ヘテロ二量体抗体およびその抗原結合断片 Download PDF

Info

Publication number
JP2024517671A
JP2024517671A JP2023565204A JP2023565204A JP2024517671A JP 2024517671 A JP2024517671 A JP 2024517671A JP 2023565204 A JP2023565204 A JP 2023565204A JP 2023565204 A JP2023565204 A JP 2023565204A JP 2024517671 A JP2024517671 A JP 2024517671A
Authority
JP
Japan
Prior art keywords
amino acid
acid residue
region
polypeptide complex
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023565204A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024517671A5 (https=
Inventor
ジョウ，ジェンハオ
ジャーン，ジエ
Original Assignee
チマゲン・バイオサイエンシズ，リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by チマゲン・バイオサイエンシズ，リミテッド filed Critical チマゲン・バイオサイエンシズ，リミテッド
Publication of JP2024517671A publication Critical patent/JP2024517671A/ja
Publication of JP2024517671A5 publication Critical patent/JP2024517671A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023565204A 2021-04-23 2022-04-22 ヘテロ二量体抗体およびその抗原結合断片 Pending JP2024517671A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/089400 2021-04-23
CN2021089400 2021-04-23
PCT/CN2022/088386 WO2022223016A1 (en) 2021-04-23 2022-04-22 Heterodimeric antibodies and antigen-binding fragment thereof

Publications (2)

Publication Number Publication Date
JP2024517671A true JP2024517671A (ja) 2024-04-23
JP2024517671A5 JP2024517671A5 (https=) 2025-05-01

Family

ID=83721948

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023565204A Pending JP2024517671A (ja) 2021-04-23 2022-04-22 ヘテロ二量体抗体およびその抗原結合断片

Country Status (7)

Country Link
US (1) US20240182576A1 (https=)
EP (1) EP4326772A4 (https=)
JP (1) JP2024517671A (https=)
CN (1) CN117597361A (https=)
AU (1) AU2022261269A1 (https=)
CA (1) CA3217487A1 (https=)
WO (1) WO2022223016A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202506741A (zh) * 2023-04-06 2025-02-16 美商麥迪紐有限責任公司 工程化抗體
WO2025103355A1 (zh) * 2023-11-14 2025-05-22 信达生物制药(苏州)有限公司 抗egfr和her3双特异性抗体-药物偶联物及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019520063A (ja) * 2016-05-26 2019-07-18 チールー ピュージェット サウンド バイオセラビューティクス コーポレイション 抗体の混合物
CN110357960A (zh) * 2018-04-10 2019-10-22 广州爱思迈生物医药科技有限公司 抗体及抗体改造方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS60499B1 (sr) * 2011-12-20 2020-08-31 Medimmune Llc Modifikovani polipeptidi za bispecifične skelete antitela
UY35148A (es) * 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US10118971B2 (en) * 2013-03-13 2018-11-06 Ibentrus, Inc. Protein in which electrical interaction is introduced within hydrophobic interaction site and preparation method therefor
ES2936810T3 (es) * 2014-05-16 2023-03-22 Pfizer Anticuerpos biespecíficos con interfaces CH1-CL de ingeniería
WO2016172485A2 (en) * 2015-04-24 2016-10-27 Genentech, Inc. Multispecific antigen-binding proteins
KR102669686B1 (ko) * 2015-04-28 2024-05-29 자임워크스 비씨 인코포레이티드 변형된 항원 결합 폴리펩티드 작제물 및 이의 용도
CA2998174A1 (en) * 2015-09-15 2017-03-23 Amgen Inc. Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof
CR20180365A (es) * 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
MX2019005552A (es) * 2016-11-14 2019-08-12 Amgen Inc Proteinas de union a antigenos biespecificas o biparatopicas y usos de las mismas.
WO2020028269A2 (en) * 2018-07-30 2020-02-06 Invenra Inc. Multispecific treg binding molecules
AU2019412561A1 (en) * 2018-12-24 2021-08-12 Sanofi Multispecific binding proteins with mutant Fab domains
CN111484555B (zh) * 2019-01-28 2022-07-08 正大天晴药业集团股份有限公司 新型双特异性cd3/cd20多肽复合物
JP7500619B2 (ja) * 2019-05-30 2024-06-17 アムジエン・インコーポレーテツド 抗体の二量体化を促進するためのヒンジ領域の操作

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019520063A (ja) * 2016-05-26 2019-07-18 チールー ピュージェット サウンド バイオセラビューティクス コーポレイション 抗体の混合物
CN110357960A (zh) * 2018-04-10 2019-10-22 广州爱思迈生物医药科技有限公司 抗体及抗体改造方法

Also Published As

Publication number Publication date
US20240182576A1 (en) 2024-06-06
EP4326772A4 (en) 2025-03-05
WO2022223016A1 (en) 2022-10-27
CN117597361A (zh) 2024-02-23
AU2022261269A1 (en) 2023-11-09
EP4326772A1 (en) 2024-02-28
CA3217487A1 (en) 2022-10-27

Similar Documents

Publication Publication Date Title
US20230348627A1 (en) Anti-4-1bb-anti-pd-l1 bispecific antibody, and pharmaceutical composition and use thereof
CN119039441A (zh) 与nkp30结合的抗体分子及其用途
US12606622B2 (en) Heteromultimeric proteins and methods of use thereof
CN121779568A (zh) 与t细胞结合的多功能分子及其治疗自身免疫性病症的用途
CN116888153A (zh) 与γ-δT细胞受体结合的抗体
WO2023006082A1 (zh) 抗原靶向、抗cd16a和免疫效应细胞激活三功能融合蛋白及其应用
EP4640708A1 (en) Novel anti-gprc5d antibody
WO2023036270A1 (zh) 抗原靶向、抗cd16a和免疫效应细胞激活三功能融合蛋白及其应用
TW202334233A (zh) 結合γδ T細胞之多肽及其用途
US20240182576A1 (en) Heterodimeric antibodies and antigen-binding fragment thereof
CN119698294A (zh) 结合γ-δT细胞受体的变体抗体
WO2025162031A1 (zh) 一种靶向TfR1的单域抗体及其应用
WO2024027120A1 (en) Multi-specific polypeptide complexes
JP7671356B2 (ja) 安定性および発現が改良されたポリペプチド複合体
WO2024149381A1 (en) Multi-specific polypeptide complexes
WO2025026282A1 (en) Modified type e multi-specific antibodies
EP4640715A1 (en) Multi-specific polypeptide complex targeting gprc5d
TWI830124B (zh) 具有改善的穩定性和表現的多肽複合物
WO2025092987A9 (zh) 基于Fc区的异二聚体分子及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250422

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250422

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260213